CNDR Welcomes Dr. Hugh McMillan as New Pediatric Lead

Dr. Hugh McMillan profile picture.

Dr. Hugh McMillan

The Canadian Neuromuscular Disease Registry (CNDR) announced in February 2024 that Pediatric Lead Dr. Craig Campbell has decided to step down from his role, passing the torch to Dr. Hugh McMillan.

As the registry embarks on this transition, the CNDR warmly welcome Dr. McMillan as the new Pediatric Lead and are grateful for the wealth of knowledge, expertise, and leadership he will bring to the role.

 

Dr. Craig Campbell

National Principal Investigator Dr. Lawrence Korngut, CNDR investigators, and the CNDR National Office Team extend their heartfelt gratitude to Dr. Craig Campbell for his exceptional contributions and passionate support as co-founder and Pediatric Lead for the CNDR. Since the inception of the CNDR, Dr. Campbell has played a pivotal role, co-founding the registry in 2010. He has been integral to multiple disease working groups, including SMA, DMD, LGMD, DM, and CMS, offering invaluable guidance and expertise. As the CNDR’s Pediatric Lead Investigator, he has been instrumental in navigating the complex landscape of neuromuscular research, ensuring CNDR’s activities align with the evolving needs of their community. Dr Campbell, alongside Victoria Hodgkinson, also worked to integrate the CNDR within the global neuromuscular registry network of TREAT-NMD, and for 6 years led the global registry committee TGDOC, based largely on the strength and substantial contributions of the CNDR to the international efforts to make an impact for children and families living with neuromuscular diseases. Dr. Campbell’s passion and leadership have been catalysts in fostering collaboration and driving impactful outcomes for patients, and the CNDR are gratitude for his dedication and commitment. 

CNDR logo4x3

Read next...

Hope On The Horizon: Trials Treatments and Therapies for DMD, DM1 and MG

Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG

Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!

Website - 2026 NMD4C Awards Now Open

2026 Awards Now Open for Nominations!

We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.

AGAMREE (vamorolone) Approved treatment for DMD in Canada

A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada

Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.